The COMBAT PRS system has already reported successful efficacy and tolerability outcomes. Further results will be presented during 2018.

For the latest Clinical Evidence click here.

References and Publications

1. Sánchez-García, S., Villarejo-Campos, P., Padilla-Valverde, D., Amo-Salas, M. & Martín-Fernández, J. Intraperitoneal chemotherapy hyperthermia (HIPEC) for peritoneal carcinomatosis of ovarian cancer origin by fluid and CO2 recirculation using the closed abdomen technique (PRS-1.0 Combat): A clinical pilot study. Int. J. Hyperth. 32, 488–495(2016).
2. Sánchez-García, S., Padilla-Valverde, D., Villarejo-Campos, P., García-Santos, E. P. & Martín-Fernández, J. Hyperthermic chemotherapy intra-abdominal laparoscopic approach: development of a laparoscopic model using CO2 recirculation system and clinical translation in peritoneal carcinomatosis. Int. J. Hyperth. 33, 684–689 (2017).
3. Sánchez-García, S. et al. Experimental development of an intra-abdominal chemohyperthermia model using a closed abdomen technique and a PRS-1.0 Combat CO2 recirculation system. Surg. (United States) 155, 719–725 (2014).
4. Sánchez-García, S., Villarejo-Campos, P., Padilla-Valverde, D., et al. Hyperthermic Intraperitoneal Chemotherapy with Paclitaxel in Advanced Ovarian Cancer. Preliminary results of clinical trial 10-008, EudraCT 2011-006319-69, NCT02681432. Presented Oral Communication. Congreso SEOQ y Reunión GECOP, Palma de Mallorca, España, 8-10 noviembre 2017.